NEUARTIGE CYTOKINE

cDNA prepared by extracting mRNA from the interstitial cells of the human bone marrow was expressed, after being cloned, with the cells of a mammal. A protein having an activity of inhibiting adipocyte formation was separated from the cell culture supernatant having such an activity and purified. Th...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	OHSUMI, JUN, TAKIGUCHI, YO, KAWASHIMA, ICHIRO, MIYADAI, KENJI
Format:	Patent
Sprache:	ger
Schlagworte:	BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS THEREOF CULTURE MEDIA ENZYMOLOGY FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIREDCHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERSFROM A RACEMIC MIXTURE HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY MICROBIOLOGY MICROORGANISMS OR ENZYMES MUTATION OR GENETIC ENGINEERING ORGANIC CHEMISTRY PEPTIDES PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES PROCESSES USING MICROORGANISMS PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS SPIRITS VINEGAR WINE
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	cDNA prepared by extracting mRNA from the interstitial cells of the human bone marrow was expressed, after being cloned, with the cells of a mammal. A protein having an activity of inhibiting adipocyte formation was separated from the cell culture supernatant having such an activity and purified. The protein was found to have an apparent molecular weight of about 23,000 by conducting SDS-PAGE electrophoresis under a reducing condition and have an N-terminal proline residue as a result of identification of the N-terminal amino acid sequence by Edman degradation. The total primary structure of the protein was determined by the above-mentioned finding and the result of genetic cloning described above to reveal that it is a cytokine having an activity of inhibiting adipocyte formation and a new structure. Thus it has become possible to produce a novel adipocyte formation inhibitor in a large amount by the recombined DNA technology and to diagnose and treat various cytopeniae and other diseases.